Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

(2013) Joel Kremer et al.   ANNALS OF INTERNAL MEDICINE

Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks

(2013) Xin-Min Li et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab

(2012) Hennie G Raterman et al.   ANNALS OF THE RHEUMATIC DISEASES

Proteomic profiling following immunoaffinity capture of high-density lipoprotein: Association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis

(2012) Junji Watanabe et al.   ARTHRITIS AND RHEUMATISM

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy

(2012) Jeffrey R. Curtis et al.   ARTHRITIS CARE & RESEARCH

Measurement of Reverse Cholesterol Transport Pathways in Humans: In Vivo Rates of Free Cholesterol Efflux, Esterification, and Excretion

(2012) Scott Turner et al.   Journal of the American Heart Association

Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis

(2011) Amit V. Khera et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study

(2010) A. Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives

(2010) G. D. Kitas et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London

Lipoprotein Subclasses Determined by Nuclear Magnetic Resonance Spectroscopy and Coronary Atherosclerosis in Patients with Rheumatoid Arthritis

(2010) C. P. CHUNG et al.   JOURNAL OF RHEUMATOLOGY

Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis

(2009) Christina Charles-Schoeman et al.   ARTHRITIS AND RHEUMATISM

Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis

(2009) Manfredi Rizzo et al.   ATHEROSCLEROSIS

Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages

(2008) Allison B. Reiss et al.   ARTHRITIS AND RHEUMATISM